OSMOPREP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OSMOPREP (OSMOPREP).
Osmotic laxative. Sodium phosphate draws water into the intestinal lumen via osmotic gradient, increasing intraluminal pressure and stimulating peristalsis.
| Metabolism | Systemic absorption via gastrointestinal tract. Excreted primarily in urine as inorganic phosphate. Not metabolized by CYP450 enzymes. |
| Excretion | Osmoprep (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) is not significantly absorbed systemically; the majority of the administered dose remains in the gastrointestinal tract and is eliminated in the feces. Less than 1% of the dose is absorbed and subsequently excreted unchanged in the urine via renal filtration. |
| Half-life | The terminal elimination half-life of the absorbed fraction is approximately 2.7 hours. This short half-life indicates rapid renal clearance of the small amount absorbed; however, the clinical effect (bowel cleansing) is independent of systemic elimination. |
| Protein binding | Negligible protein binding (< 1%) due to minimal systemic absorption; phosphate ions are freely filtered and reabsorbed in the kidneys. |
| Volume of Distribution | The apparent volume of distribution of absorbed phosphate is approximately 0.25 L/kg, approximating extracellular fluid volume, consistent with its distribution in the body. |
| Bioavailability | Oral bioavailability is less than 1% due to poor gastrointestinal absorption; the vast majority of the dose remains locally in the gut lumen to exert its osmotic laxative effect. |
| Onset of Action | Oral administration: Onset of action (first bowel movement) occurs approximately 0.5 to 3 hours after the first dose, with the maximum purgative effect typically within 1-2 hours. |
| Duration of Action | After the final dose, bowel evacuation persists for 2 to 4 hours. The duration of bowel cleansing effect covers the entire preparation period (typically 4-6 hours from the start of dosing). |
3 tablets orally in the evening before colonoscopy, followed by 3 tablets the next morning, each dose with at least 1.5 L of clear liquids; maximum 6 tablets total.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if creatinine clearance < 30 mL/min; no dose adjustment defined for GFR 30-89 mL/min. |
| Liver impairment | No specific adjustment based on Child-Pugh score; use caution in severe hepatic impairment due to risk of electrolyte abnormalities. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended; monitor renal function and electrolyte status closely due to increased risk of renal impairment and dehydration. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OSMOPREP (OSMOPREP).
| Breastfeeding | It is not known whether sodium phosphate is excreted in human milk. The molecular weight is low, and systemic absorption after oral administration is minimal. However, caution is advised when administering to a nursing woman. M/P ratio is not available. Consider delaying breastfeeding until after the laxative effect has resolved (typically 24-48 hours) to avoid any possible infant exposure or diarrhea. |
| Teratogenic Risk | OSMOPREP (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of sodium phosphate salts to pregnant rats during organogenesis at doses up to 0.5 times the maximum recommended human dose (MRHD) did not reveal evidence of fetal harm. However, hypocalcemia and electrolyte imbalances in the mother may pose risks to the fetus, especially in the third trimester when bowel preparation could induce premature labor or fetal distress. Use only if clearly needed. |
■ FDA Black Box Warning
Acute phosphate nephropathy (AKI due to calcium phosphate deposition in renal tubules) has been reported with use of oral sodium phosphate bowel cleansing products, especially in patients at increased risk (e.g., pre-existing kidney disease, advanced age, volume depletion, or those taking medications affecting renal function).
| Serious Effects |
["Known hypersensitivity to sodium phosphate or any component of the formulation","Bowel obstruction or ileus","Gastric retention","Gastrointestinal perforation","Toxic colitis or toxic megacolon","Severe renal impairment (eGFR <30 mL/min/1.73 m²)","Patients with a history of acute phosphate nephropathy","Pregnancy (category C, but limited data; use only if clearly needed)"]
| Precautions | ["Risk of acute phosphate nephropathy: monitor renal function before use; avoid in patients with impaired renal function, advanced age, or volume depletion.","Electrolyte abnormalities: hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia; monitor electrolytes in patients with risk factors.","Seizures: most commonly associated with electrolyte abnormalities (e.g., hypocalcemia, hyponatremia).","Cardiac arrhythmias: QT prolongation, especially with electrolyte imbalances.","Colonic mucosal ulcerations: reported with sodium phosphate preparations.","Dehydration: ensure adequate hydration before, during, and after use."] |
Loading safety data…
| Fetal Monitoring | Monitor serum electrolytes (especially calcium, phosphate, potassium, sodium), renal function (serum creatinine, BUN), and volume status before and during administration. Monitor for signs of hypocalcemia (tetany, paresthesias, seizures) and hyperphosphatemia. Fetal monitoring should include fetal heart rate assessment if preterm labor is suspected. Monitor for premature contractions and changes in cervical status. |
| Fertility Effects | There are no specific studies on fertility effects in humans. In rats, oral administration of sodium phosphate salts at doses up to 0.5 times the MRHD had no adverse effects on male or female fertility. Theoretical risk of electrolyte disturbances affecting reproductive hormone levels or gamete function is minimal with single-dose use. |